Free Shipping On Orders Over $1,000!

TLR4 Polyclonal Antibody, PE-Cy5 Conjugated

Applications

  • WB
  • FCM

Reactivity

  • Human
  • Mouse
  • Rat
  • Cow

Predicted Reactivity

  • Sheep
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-20594R-PE-Cy5
Product Name TLR4 Polyclonal Antibody, PE-Cy5 Conjugated
Applications WB, FCM
Reactivity Human, Mouse, Rat, Cow
Predicted Reactivity Sheep, Pig, Horse, Rabbit
Specifications
Conjugation PE-Cy5
Host Rabbit
Source KLH conjugated synthetic peptide derived from human TLR4
Immunogen Range 701-800/839
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 7099
Swiss Prot O00206
Subcellular location Cell membrane
Synonyms Toll-like receptor 4; TLR4; CD284
Background Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:9237759, PubMed:10835634). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. Responses triggered by Ni2+ require non-conserved histidines and are, therefore, species-specific (PubMed:20711192). Both M.tuberculosis HSP70 (dnaK) and HSP65 (groEL-2) act via this protein to stimulate NF-kappa-B expression (PubMed:15809303). In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL-) and mediates the cytokine release induced by LDL- (PubMed:23880187).
Application Dilution
WB 1:300-5000
FCM 1:20-100